{"id":56100,"date":"2023-04-21T19:06:23","date_gmt":"2023-04-21T17:06:23","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/clinical-study-of-over-1000-transplant-recipients-demonstrates-improved-clinical-outcomes-in-heart-transplantation-with-the-paragonix-sherpapak\/"},"modified":"2023-04-21T19:06:23","modified_gmt":"2023-04-21T17:06:23","slug":"clinical-study-of-over-1000-transplant-recipients-demonstrates-improved-clinical-outcomes-in-heart-transplantation-with-the-paragonix-sherpapak","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/clinical-study-of-over-1000-transplant-recipients-demonstrates-improved-clinical-outcomes-in-heart-transplantation-with-the-paragonix-sherpapak\/","title":{"rendered":"Clinical Study of Over 1,000 Transplant Recipients Demonstrates Improved Clinical Outcomes in Heart Transplantation with the Paragonix SherpaPak"},"content":{"rendered":"
\n

\nNew GUARDIAN-Heart dataset presented at the 43rd ISHLT Annual Meeting & Scientific Sessions demonstrates that the Paragonix SherpaPak significantly reduced the likelihood of Severe Primary Graft Dysfunction, a life-threatening complication shown to diminish patient survival rates.<\/i><\/p>\n

<\/a><\/p>\n

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Paragonix Technologies, Inc.<\/a>, a leading organ transplant company, announces that the latest clinical report of over 1,000 transplant patients studied in the GUARDIAN-Heart Registry was presented at the 2023 ISHLT Annual Meeting & Scientific Sessions. GUARDIAN clinical investigators and 21 independent transplant centers presented extensive findings in over 20 presentations throughout the conference, detailing the impact of advanced donor heart preservation and the clinical benefits that transplant recipients experienced with the use of the Paragonix SherpaPak Cardiac Transport System.<\/p>\n

\nThe conclusions of multiple research presentations highlighted that the use of a Paragonix SherpaPak system is associated with a reduction in common post-transplant complications, as well as an increase in survival rates. Notably, the most impactful results consistently demonstrate a significant reduction in Severe Primary Graft Dysfunction (PGD), a serious post-transplant complication. Dr. Andreas Zuckermann, a renowned cardiothoracic surgeon at the University of Vienna (Austria), also presented data at the conference showing that patients who experience Severe PGD after a heart transplant have an over 677% or almost 8 times higher risk of mortality (p=<0.001) within the span of one year, highlighting the severity of this complication on patient survival.1<\/sup><\/p>\n

\n\u201cThe findings of this analysis confirm our hypothesis that Primary Graft Dysfunction, especially Severe PGD, can have a notable and potentially hazardous effect on the survival of heart transplant recipients, both in the immediate post-operative period and at the 1-year mark. It will be very interesting to evaluate longer follow-up to estimate the impact on long term survival,\u201d said Dr. Andreas Zuckermann.<\/p>\n

\nDuring the conference, Dr. David D’Alessandro, US Principal Investigator of the GUARDIAN study, Associate Chief of Clinical Operations in Cardiac Surgery, and Associate Professor of Surgery at Massachusetts General Hospital, presented data showing that the Paragonix SherpaPak reduced the incidence of Severe PGD by 36% in a study of over 1000 patients. Further analysis revealed that the rate of reduction increased to over 50% in over 550 patients who were propensity matched based on donor characteristics.2<\/sup> Multiple other presentations that examined subpopulations of the GUARDIAN-Heart Registry also demonstrated a consistent trend of decreased incidence of Severe Primary Graft Dysfunction (PGD) and improved post-transplant outcomes, including:<\/p>\n

\nExtended Criteria Donors3<\/sup> (Donor Pool Expansion)<\/b><\/p>\n